Zealand Pharma — Juni 2023
-
Jeg kan blot sige at jeg sidder rolig i båden. Jeg ser ikke at noget fundamentalt er ændret ved casen for mig.
-
Eliot: her er link til fase 3 med Semaglutide i NASH https://classic.clinicaltrials.gov/ct2/show/NCT04822181
-
Eliot: fandt data fra BI. dem der fik højeste dosis (4,8mg) titrerede over 20 uger. Så samme længde med Wegovy
-
The Phase II, randomized, parallel group, dose-finding study evaluated once-weekly subcutaneously administered survodutide for 46 weeks compared with placebo in people with overweight or obesity without type 2 diabetes.1 The trial included 20 weeks of dosing escalation and 26 weeks of maintenance and evaluated doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg.
-
Så patienterne har haft 5 uger på hver dosis vs 4 uger for Wegovy. Det bliver godt nok en lang periode hvis de vil forlænge perioden mellem hver dosis
-
-
Troldmanden - Tak for alt det fine info du har leveret. Her er lidt at tygge på.
-
Der store kræfter i spil indenfor behandling af korttarmssyndrom hvilket vi kunne se i forbindelse med Ironwoods køb af VectivBio, hvor Ironwood tilsyneladende har anslået at Apraglutide er 1,1 mia. dollar værd, endda uden at Fase 3 data er på plads. Eksemplet illustrerer ganske godt at aktiekurser til tider kan være helt ude af sync.
-
"The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days."
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
- Transaction Advances Ironwood’s Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share
(investor.ironwoodpharma.com)
-
At the end of the day tror jeg, at vi oplever en storm I et glas vand. Hvis Zeal er ligeså meget fup som Quantafuel(som gjorde avs) - giver jeg op på aktiemarkedet. Jeg kan slet ikke forestille mig at Adam S er fake og ikke har styr på butikken. Come monday....
-
Helt fair at sælge YPE, hvis du forventer yderligere væsentlige fald. Jeg forventer, at det går som tidligere, hvor træet er blevet rystet. En pludselig vending og en større stigning, og inden vi får set os om, er vi tilbage. Ingen
fundamentale ændringer for at se, men et sammenfald af flere andre faktorer. Time will tell. -
YPE - Det er vigtigt at stole på sin egen mavefornemmelse og med 100% afkast er der kun grund til at være tilfreds.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind